FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry, and in particular to a method of reducing extracellular matrix-producing cells in the lungs or suppressing an increase in extracellular matrix-producing cells in the lungs (variants) and a composition for reducing extracellular matrix-producing cells in the lungs or suppressing an increase in extracellular matrix-producing cells in the lungs.
EFFECT: above composition effectively reduces extracellular matrix-producing cells in the lungs.
11 cl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT APPLICABLE IN PULMONARY FIBROSIS | 2009 |
|
RU2547571C2 |
| COMPOSITION FOR RECOVERY OF NORMAL TISSUE FROM FIBROUS TISSUE | 2011 |
|
RU2650796C2 |
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| AGENT FOR TREATING MYELOFIBROSIS | 2009 |
|
RU2557997C2 |
| MEANS FOR INTESTINAL FIBROSIS TREATMENT | 2012 |
|
RU2637372C2 |
| MATERIALS AND METHODS OF TREATING CHRONIC FIBROUS DISEASES | 2006 |
|
RU2446825C2 |
| PREVENTIVE OR THERAPEUTIC AGENT FOR TREATING FIBROSIS | 2011 |
|
RU2583290C2 |
| IMAGING AGENTS FOR FIBROUS DISEASES | 2009 |
|
RU2596495C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
